To explore the oncogenic potential of CBX2 in human leukemia, we analyzed CBX2 expression levels in 176 clinically annotated AML samples (TGCA) [16], 19 non-transformed human bone marrow progenitor samples, and 16 differentiated human monocyte and macrophage samples (blueprint cohort, https://www.blueprint-epigenome.eu) [17]. The gene discussed is CBX2; the disease is acute myeloid leukemia.